Marksans Pharma Ltd.
Fundamentals
- Market cap
- ₹11,604 cr
- P/E
- 27.77×
- ROE
- 15.43%
- Debt / equity
- 0.01
- Div yield
- 0.34%
- 52-week range
- 155.00 — 275.50
Marksans Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
The timeline — 6 notes on Marksans Pharma Ltd.
June 2026
- 09 Jun 26 · 3:14 PM IST Brief Brief · Credit · Mid cap
India Ratings lifts Marksans Pharma outlook to Positive
The rating agency affirmed the bank loan rating at IND AA- but moved the outlook to Positive, citing strong cash generation.
- 03 Jun 26 · 2:25 PM IST Brief Brief · Earnings · Mid cap
Marksans plans ₹4,000 cr revenue by FY28, but the call transcript adds nothing new
The earnings call transcript is a record of guidance already given. Management targets ₹4,000 crore revenue by FY28 and says the heavy capex cycle is over.
May 2026
- 27 May 26 · 5:41 PM IST Brief Brief · Concalls · Mid cap
Marksans shelves ₹100 cr plant, sticks to ₹4,000 cr target
Management says existing plants have room to grow. The ambitious revenue goal for FY28 is unchanged, but raw-material costs are rising fast.
- 26 May 26 · 1:31 PM IST Brief Brief · Earnings · Mid cap
Marksans closes FY26 with record ₹3,033 cr revenue as Q4 UK sales hit all-time high
Full-year profit rose 9.8% to ₹420 crore. The fourth quarter accelerated, with UK sales at a record and Australia/New Zealand revenue doubling sequentially.
- 26 May 26 · 1:15 PM IST Brief Brief · Earnings · Mid cap
Marksans Pharma profit jumps 60% on standalone basis for FY26
Standalone net profit reached ₹3,007 million as revenue climbed 14%. Consolidated profit grew at a more modest 10% to ₹4,201 million.
- 26 May 26 · 12:56 PM IST Brief Brief · Earnings · Mid cap
Marksans Pharma profit climbs 60% on standalone basis for FY26
The company reported a consolidated net profit of ₹4,201 million for the year, alongside a final dividend recommendation of ₹0.90 per share.